OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.

OnKure Therapeutics, Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on McKesson (MCK) and OnKure Therapeutics (OKUR) with b...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fractyl Health, Inc. (GUTS) and OnKure Therapeutics (OKUR). Fract...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OKUR	$4.14	-0.24%	85.01K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OKUR	$4.14	-0.2%	85.01K
3
4
5
6

OKUR

OKUR

Get OnKure Therapeutics, Inc. Data in Excel

Get OnKure Therapeutics, Inc. Data in Excel